Literature DB >> 3917671

Lupus pregnancy. II. Unusual pattern of hypocomplementemia and thrombocytopenia in the pregnant patient.

M D Lockshin, P C Harpel, M L Druzin, C G Becker, R F Klein, R M Watson, K B Elkon, E Reinitz.   

Abstract

To explore the causes of complications in pregnant women with systemic lupus erythematosus (SLE), we prospectively evaluated 34 pregnancies in 28 SLE patients, and 2 additional pregnancies in patients with lupus anticoagulant and positive antinuclear antibody, but no other manifestations of SLE. Nineteen pregnancies (55%) were complicated by marked proteinuria, thrombocytopenia, and/or lupus anticoagulant. Hypocomplementemia occurred in 18 pregnancies (52%). Neither thrombocytopenia-anticoagulant nor proteinuria was accompanied by an increase in antibody to double-stranded DNA or by clinical signs of active SLE. Antibody to Ro antigen did not predict fetal death. Both thrombocytopenia and proteinuria appeared abruptly during pregnancy and disappeared quickly after delivery. Fetal death was the result in 7 of 9 (77%) pregnancies in patients with anticoagulant, 6 of 10 (60%) in patients with thrombocytopenia, 6 of 18 (33%) in patients with hypocomplementemia, and 3 of 11 (27%) in patients with proteinuria. Twenty of 29 (68%) children were identified as male. The pathogenesis of hypocomplementemia was evaluated by a new assay, C1s-C1 inhibitor complex, which is thought to measure rate of complement activation by the classical pathway. Most pregnant patients with low CH50 levels and proteinuria had normal levels of C1s-C1 inhibitor complex, whereas nonpregnant patients with equivalent proteinuria and hypocomplementemia had high levels, as did pregnant patients with hypocomplementemia who did not have SLE. Pregnant and nonpregnant hypocomplementemic patients with proteinuria had similar levels of C3 and C4. In pregnant patients with SLE, C1s-C1 inhibitor complex was independent of CH50; in nonpregnant patients a linear relationship between C1s-C1 inhibitor complex and CH50 was seen.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3917671     DOI: 10.1002/art.1780280110

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  7 in total

Review 1.  Evaluation of the obstetrical risks of the antiphospholipid syndrome and therapeutic management.

Authors:  P Edelman; A M Rouquette
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 2.  Passively acquired autoimmunity and the maternal fetal dyad in systemic lupus erythematosus.

Authors:  J Buyon; I Szer
Journal:  Springer Semin Immunopathol       Date:  1986

Review 3.  Lupus erythematosus and allied disorders in pregnancy.

Authors:  M D Lockshin
Journal:  Bull N Y Acad Med       Date:  1987-10

Review 4.  Lupus pregnancies and neonatal lupus.

Authors:  M D Lockshin
Journal:  Springer Semin Immunopathol       Date:  1994

Review 5.  Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications.

Authors:  A M Lynch; J E Salmon
Journal:  Placenta       Date:  2010-04-27       Impact factor: 3.481

Review 6.  Systemic lupus erythematosus and pregnancy.

Authors:  R H Derksen
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

Review 7.  Predictors of pregnancy outcome in antiphospholipid syndrome: a review.

Authors:  Sara De Carolis; Angela Botta; Stefania Santucci; Serafina Garofalo; Carmelinda Martino; Alessandra Perrelli; Silvia Salvi; Sergio Ferrazzani; Leonardo Caforio; Giovanni Scambia
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.